![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZMYM6 |
Gene summary for ZMYM6 |
![]() |
Gene information | Species | Human | Gene symbol | ZMYM6 | Gene ID | 9204 |
Gene name | zinc finger MYM-type containing 6 | |
Gene Alias | Buster2 | |
Cytomap | 1p34.3 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | O95789 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9204 | ZMYM6 | HCC1_Meng | Human | Liver | HCC | 2.26e-25 | 5.01e-02 | 0.0246 |
9204 | ZMYM6 | HCC2_Meng | Human | Liver | HCC | 4.69e-15 | 6.88e-02 | 0.0107 |
9204 | ZMYM6 | HCC1 | Human | Liver | HCC | 2.36e-04 | 2.56e+00 | 0.5336 |
9204 | ZMYM6 | HCC2 | Human | Liver | HCC | 2.26e-13 | 2.98e+00 | 0.5341 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002260422 | Liver | HCC | regulation of cell morphogenesis | 188/7958 | 309/18723 | 4.84e-11 | 1.82e-09 | 188 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZMYM6 | SNV | Missense_Mutation | novel | c.3041N>A | p.Arg1014His | p.R1014H | O95789 | protein_coding | tolerated_low_confidence(0.06) | probably_damaging(0.972) | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZMYM6 | SNV | Missense_Mutation | rs750502313 | c.2968T>G | p.Tyr990Asp | p.Y990D | O95789 | protein_coding | tolerated_low_confidence(0.19) | benign(0.209) | TCGA-A2-A0YE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
ZMYM6 | SNV | Missense_Mutation | rs750502313 | c.2968T>G | p.Tyr990Asp | p.Y990D | O95789 | protein_coding | tolerated_low_confidence(0.19) | benign(0.209) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
ZMYM6 | SNV | Missense_Mutation | c.3511G>C | p.Glu1171Gln | p.E1171Q | O95789 | protein_coding | deleterious_low_confidence(0) | benign(0.193) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ZMYM6 | SNV | Missense_Mutation | rs750502313 | c.2968N>G | p.Tyr990Asp | p.Y990D | O95789 | protein_coding | tolerated_low_confidence(0.19) | benign(0.209) | TCGA-AN-A0XR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ZMYM6 | SNV | Missense_Mutation | c.964N>A | p.His322Asn | p.H322N | O95789 | protein_coding | tolerated_low_confidence(0.25) | benign(0.014) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
ZMYM6 | SNV | Missense_Mutation | c.2932C>G | p.Leu978Val | p.L978V | O95789 | protein_coding | tolerated(0.22) | benign(0.033) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
ZMYM6 | SNV | Missense_Mutation | c.1010N>T | p.Ser337Leu | p.S337L | O95789 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.93) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ZMYM6 | SNV | Missense_Mutation | rs750502313 | c.2968N>G | p.Tyr990Asp | p.Y990D | O95789 | protein_coding | tolerated_low_confidence(0.19) | benign(0.209) | TCGA-E9-A1NF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
ZMYM6 | insertion | Nonsense_Mutation | novel | c.3498_3499insTGAGT | p.Pro1167Ter | p.P1167* | O95789 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |